MANNKIND CORP Net Cash Provided by (Used in) Operating Activities, Continuing Operations
MANNKIND CORP (MNKD) reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of -$37.73 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-26.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2019-02-26
- MANNKIND CORP net cash provided by (used in) operating activities, continuing operations for the quarter ending 2018-12-31 was $24.99M.
- MANNKIND CORP net cash provided by (used in) operating activities, continuing operations for the quarter ending 2018-09-30 was -$13.92M.
- MANNKIND CORP net cash provided by (used in) operating activities, continuing operations for the quarter ending 2018-06-30 was -$27.15M.
- MANNKIND CORP net cash provided by (used in) operating activities, continuing operations for the quarter ending 2018-03-31 was -$21.65M, a 354.50% decline year-over-year.
- MANNKIND CORP net cash provided by (used in) operating activities, continuing operations for fiscal 2018 was -$37.73M.
- MANNKIND CORP net cash provided by (used in) operating activities, continuing operations for fiscal 2017 was -$64.78M.
- MANNKIND CORP net cash provided by (used in) operating activities, continuing operations for fiscal 2016 was -$78.09M.
- MANNKIND CORP net cash provided by (used in) operating activities, continuing operations for fiscal 2015 was -$57.23M, a 1500.69% decline from fiscal 2014.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 277 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 280 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 283 month |
|---|---|---|---|---|---|---|---|
| 2018-12-31 | $24.99M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $11.07M derived: sum of 2 quarters · filed 2019-02-26 | -$16.08M derived: sum of 3 quarters · filed 2019-02-26 | -$37.73M 10-K · filed 2019-02-26 | |||
| 2018-09-30 | -$13.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$41.07M derived: sum of 2 quarters · filed 2018-11-01 | -$62.72M 10-Q · filed 2018-11-01 | -$92.70M derived: sum of 4 quarters · filed 2018-11-01 | |||
| 2018-06-30 | -$27.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$48.80M 10-Q · filed 2018-08-02 | -$78.78M derived: sum of 3 quarters · filed 2018-08-02 | -$102.05M derived: sum of 4 quarters · filed 2018-08-02 | |||
| 2018-03-31 | -$21.65M 10-Q · filed 2018-05-09 | -$51.63M derived: sum of 2 quarters · filed 2018-05-09 | -$74.90M derived: sum of 3 quarters · filed 2018-05-09 | -$94.94M derived: sum of 4 quarters · filed 2018-05-09 | |||
| 2017-12-31 | -$29.98M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$53.25M derived: sum of 2 quarters · filed 2018-02-27 | -$73.28M derived: sum of 3 quarters · filed 2018-02-27 | -$64.78M 10-K · filed 2018-02-27 | |||
| 2017-09-30 | -$23.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$43.30M derived: sum of 2 quarters · filed 2017-11-07 | -$34.80M 10-Q · filed 2017-11-07 | -$47.55M derived: sum of 4 quarters · filed 2018-05-09 | |||
| 2017-06-30 | -$20.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | -$11.53M 10-Q · filed 2017-08-07 | -$24.28M derived: sum of 3 quarters · filed 2018-05-09 | -$47.35M derived: sum of 4 quarters · filed 2018-05-09 | |||
| 2017-03-31 | $8.51M 10-Q · filed 2018-05-09 | -$4.25M derived: sum of 2 quarters · filed 2018-05-09 | -$27.32M derived: sum of 3 quarters · filed 2018-05-09 | -$38.83M derived: sum of 4 quarters · filed 2018-05-09 | |||
| 2016-12-31 | -$12.75M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$35.82M derived: sum of 2 quarters · filed 2018-02-27 | -$47.33M derived: sum of 3 quarters · filed 2018-02-27 | -$78.09M 10-K · filed 2018-02-27 | |||
| 2016-09-30 | -$23.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$34.58M derived: sum of 2 quarters · filed 2017-11-07 | -$65.34M 10-Q · filed 2017-11-07 | -$87.89M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-06-30 | -$11.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | -$42.27M 10-Q · filed 2017-08-07 | -$64.82M derived: sum of 3 quarters · filed 2018-02-27 | -$84.71M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-03-31 | -$30.76M 10-Q · filed 2017-05-10 | -$53.31M derived: sum of 2 quarters · filed 2018-02-27 | -$73.20M derived: sum of 3 quarters · filed 2018-02-27 | -$91.01M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2015-12-31 | -$22.55M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$42.44M derived: sum of 2 quarters · filed 2018-02-27 | -$60.25M derived: sum of 3 quarters · filed 2018-02-27 | -$57.23M 10-K · filed 2018-02-27 | |||
| 2015-09-30 | -$19.89M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2016-11-09 | -$37.70M derived: sum of 2 quarters · filed 2016-11-09 | -$34.68M 10-Q · filed 2016-11-09 | -$70.42M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-06-30 | -$17.81M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2016-08-10 | -$14.79M 10-Q/A · filed 2016-08-10 | -$50.53M derived: sum of 3 quarters · filed 2017-03-16 | $49.70M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-03-31 | $3.02M 10-Q · filed 2016-05-09 | -$32.72M derived: sum of 2 quarters · filed 2017-03-16 | $67.51M derived: sum of 3 quarters · filed 2017-03-16 | $44.10M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | -$35.74M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $64.49M derived: sum of 2 quarters · filed 2017-03-16 | $41.08M derived: sum of 3 quarters · filed 2017-03-16 | $4.09M 10-K · filed 2017-03-16 | |||
| 2014-09-30 | $100.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $76.82M derived: sum of 2 quarters · filed 2015-11-09 | $39.83M 10-Q · filed 2015-11-09 | $5.78M derived: sum of 4 quarters · filed 2016-03-15 | -$1.69B 10-Q · filed 2014-11-10 | ||
| 2014-06-30 | -$23.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | -$60.41M 10-Q · filed 2015-08-10 | -$94.46M derived: sum of 3 quarters · filed 2016-03-15 | -$127.37M derived: sum of 4 quarters · filed 2016-03-15 | -$1.79B 10-Q · filed 2014-08-11 | ||
| 2014-03-31 | -$36.99M 10-Q · filed 2015-05-11 | -$71.04M derived: sum of 2 quarters · filed 2016-03-15 | -$103.95M derived: sum of 3 quarters · filed 2016-03-15 | -$133.69M derived: sum of 4 quarters · filed 2016-03-15 | -$1.76B 10-Q · filed 2014-05-12 | ||
| 2013-12-31 | -$34.05M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$66.96M derived: sum of 2 quarters · filed 2016-03-15 | -$96.70M derived: sum of 3 quarters · filed 2016-03-15 | -$128.73M 10-K · filed 2016-03-15 | |||
| 2013-09-30 | -$32.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$62.65M derived: sum of 2 quarters · filed 2014-11-10 | -$94.68M 10-Q · filed 2014-11-10 | ||||
| 2013-06-30 | -$29.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$61.77M 10-Q · filed 2014-08-11 | |||||
| 2013-03-31 | -$32.03M 10-Q · filed 2014-05-12 | ||||||
| 2012-12-31 | -$119.86M 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |